Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.41 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13891383 | 1.00 | ALDH1A1 (0.47) | ALDH1A1KMT2AMEN1MAPTNPSR1 | |
| SCHEMBL4222516 | 1.00 | ALDH1A1 (0.47) | ALDH1A1KMT2AMEN1MAPTNPSR1 | |
| SCHEMBL13878620 | 0.90 | KMT2A (0.47) | ALDH1A1KMT2AMEN1MAPTNPSR1 | |
| SCHEMBL4212571 | 0.90 | KMT2A (0.47) | ALDH1A1KMT2AMEN1MAPTNPSR1 | |
| SCHEMBL13891347 | 0.90 | KMT2A (0.47) | ALDH1A1KMT2AMEN1MAPTNPSR1 | |
| SCHEMBL4216875 | 0.88 | GAA (0.51) | ALDH1A1KMT2AMEN1USP2SMN1; SMN2 | |
| SCHEMBL13878649 | 0.88 | GAA (0.51) | ALDH1A1KMT2AMEN1USP2SMN1; SMN2 | |
| SCHEMBL13878604 | 0.87 | KMT2A (0.47) | ALDH1A1KMT2AMEN1USP2SMN1; SMN2 | |
| SCHEMBL19173550 | 0.87 | KMT2A (0.47) | ALDH1A1KMT2AMEN1USP2SMN1; SMN2 | |
| SCHEMBL4217146 | 0.87 | KMT2A (0.47) | ALDH1A1KMT2AMEN1USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090093463-A1 | NOVEL COMPOUNDS OF SUBSTITUTED AND UNSUBTITUTED ADAMANTYL AMIDES | AGOURON PHARMACEUTICALS INC. (US) | 2009-04-09 | — | — | US | disclosed |
| US-20090093463-A1 | NOVEL COMPOUNDS OF SUBSTITUTED AND UNSUBTITUTED ADAMANTYL AMIDES | AGOURON PHARMACEUTICALS INC. (US) | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093463-A1 | NOVEL COMPOUNDS OF SUBSTITUTED AND UNSUBTITUTED ADAMANTYL AMIDES | HSD11B1, HSD11B2, HSD17B11 | ALDH1A1 50/4885KMT2A 3107/4885MEN1 2198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.